Scarica l'app Stockscreener
2.08
0.00%
0.00
Dopo l'orario di chiusura:
2.08
Precedente Chiudi:
$2.08
Aprire:
$2.06
Volume 24 ore:
125.62K
Relative Volume:
0.17
Capitalizzazione di mercato:
$69.82M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.52
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
-13.69%
1M Prestazione:
+23.81%
6M Prestazione:
+1.96%
1 anno Prestazione:
-75.59%
Intervallo 1D:
$2.06
$2.09
Intervallo di 1 settimana:
$2.02
$2.45
Portata 52W:
$0.87
$8.70
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.08 | 89.14M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - Autocar Professional
What analysts say about Outlook Therapeutics Inc. stockFree Capital Growth Strategies - Autocar Professional
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Outlook Therapeutics Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment - Stock Titan
What drives Outlook Therapeutics Inc. stock priceSignificant capital appreciation - Autocar Professional
Is Outlook Therapeutics Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week - simplywall.st
Outlook Therapeutics(OTLK) Drops 4.15% Amid Biotech Volatility - AInvest
How Outlook Therapeutics Inc. stock performs during market volatilityCapital Doubling Tips - Newser
Why Outlook Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser
What makes Outlook Therapeutics Inc. stock price move sharplyFree Expert-Led Investment Training - Newser
Outlook Therapeutics (OTLK) Soars 12.08% on Clinical Trial Success - AInvest
Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus PT from Analysts - Defense World
Outlook Therapeutics shares rise 3.12% intraday after recent Federal Circuit's Disclosure-Level Test In In Re Riggs. - AInvest
What caused OTLK's net profit surge in Q3 2024? - AInvest
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
Outlook Therapeutics announces CEO appointment - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Outlook Therapeutics Appoints New CEO Robert Charles Jahr - The Globe and Mail
Outlook Therapeutics Appoints Bob Jahr as CEO - citybiz
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer | OTLK Stock News - GuruFocus
Outlook Therapeutics Taps 20-Year Biotech Veteran Bob Jahr as CEO During Crucial Product Launch Phase - Stock Titan
Outlook Therapeutics, Inc.(NasdaqCM: OTLK) dropped from Russell 2500 Growth Index - MarketScreener
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event | OTLK Stock News - GuruFocus
Outlook Therapeutics, Inc. to Host Virtual Investor Lunch Break Event on June 25, 2025 - Nasdaq
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewswire
Outlook Therapeutics CEO Reveals Commercial Strategy and Key Milestones in Exclusive Investor Event - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook LawsuitOTLK - ACCESS Newswire
Outlook Launches Ophthalmic Bevacizumab In Germany And The UK - insights.citeline.com
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Outlook Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Brookline Capital lowers Outlook Therapeutics stock price target on cash balance By Investing.com - Investing.com South Africa
Brookline Capital lowers Outlook Therapeutics stock price target on cash balance - Investing.com Australia
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ - GuruFocus
Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD - MarketScreener
Outlook Therapeutics (OTLK) Gains SMC Approval for LYTENAVA in Scotland | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):